AusperBio has closed a $120.0M Series C round, bringing in a syndicate that includes RA Capital Management, L.P., HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, Yuanbio Venture Capital, and CDH Investments.
The near-commercial biopharma, operating across the U.S. and China, is pushing oligonucleotide and targeted delivery tech toward a functional cure for chronic hepatitis B. Its pipeline leans on proprietary platforms like Med-Oligoâ„¢ ASO and Au-HALOâ„¢ delivery, with multiple clinical-stage programs already underway. The fresh capital gives it runway to keep advancing that backbone-based combination strategy, while it also eyes expansion into other disease areas where treatment options are thin.
